Definium Therapeutics vs Heartflow
Definium Therapeutics (DFTX), health care, and Heartflow (HTFL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Heartflow is worth $4.1B on the stock market and Definium Therapeutics $4B: Heartflow is valued at 3% more. Over the past year Definium Therapeutics's share price has moved +164% and Heartflow's +71.6%.
Key facts
- Definium Therapeutics market value
- $4B
- Heartflow market value
- $4.1B
- Heartflow P/E
- 70.3
- Heartflow revenue
- $176MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Definium Therapeutics | Heartflow |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4Blower | $4.1Bhigher |
| Revenue | — | $176M |
| Earnings | -$183.8Mlower | -$116.8Mhigher |
| Employees | 105lower | 843higher |
| Total assets | $440.1Mhigher | $359.5Mlower |
| Valuation | ||
| P/E | — | 70.3 |
| P/S | — | 23.5 |
| P/B | 4.2lower | 14.6higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | — | -36.4% |
| Balance sheet | ||
| Net assets | $332.3Mhigher | $300.6Mlower |
| Total liabilities | $107.8Mhigher | $58.8Mlower |
| Total debt | $40.6M | — |
| Cash on hand | $257.8Mhigher | $44.8Mlower |
| Price change | ||
| Today | -2.59%lower | +0.45%higher |
| 1 year | +164%higher | +71.6%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Definium Therapeutics only (2)
Heartflow only (3)
- Ron Baron0.2%
- Polen Capital team<0.1%
- Temasek<0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns DFTX · Who owns HTFL
More on Definium Therapeutics
Further comparisons
Definium Therapeutics against its closest peers
Heartflow against its closest peers
Learn
Questions and answers
Which is bigger, Definium Therapeutics or Heartflow?
By market value, Heartflow is the larger: $4.1B against $4B for Definium Therapeutics.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Definium Therapeutics and Heartflow?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Definium Therapeutics and 3 hold Heartflow.
Cite this page
Funkfolio, “Definium Therapeutics vs Heartflow”, data as of 18 November 2026. https://funkfolio.com/compare/dftx-vs-htfl
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.